Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company specializing in rare respiratory diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's Chair and CEO, Matt Pauls, will present on January 15 at 5:15pm PT/8:15pm ET at the Westin St. Francis in San Francisco. The presentation will be available via live webcast and will remain accessible for 30 days on the company's website.
Savara Inc. (Nasdaq: SVRA), una compagnia biofarmaceutica in fase clinica specializzata in malattie respiratorie rare, ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare. Il presidente e CEO dell'azienda, Matt Pauls, presenterà il 15 gennaio alle 17:15 PT/20:15 ET presso il Westin St. Francis di San Francisco. La presentazione sarà disponibile tramite un webcast dal vivo e rimarrà accessibile per 30 giorni sul sito web dell'azienda.
Savara Inc. (Nasdaq: SVRA), una compañía biofarmacéutica en etapa clínica especializada en enfermedades respiratorias raras, ha anunciado su participación en la 43ª Conferencia Anual de J.P. Morgan Healthcare. El presidente y CEO de la compañía, Matt Pauls, presentará el 15 de enero a las 5:15 p.m. PT/8:15 p.m. ET en el Westin St. Francis en San Francisco. La presentación estará disponible a través de una transmisión en vivo y permanecerá accesible durante 30 días en el sitio web de la compañía.
Savara Inc. (Nasdaq: SVRA)는 드문 호흡기 질환을 전문으로 하는 임상 단계의 생명공학 회사로, 제43회 J.P. Morgan Healthcare 컨퍼런스에 참여할 것이라고 발표했습니다. 회사의 회장 겸 CEO인 Matt Pauls는 1월 15일 오후 5시 15분 PT/오후 8시 15분 ET에 샌프란시스코의 Westin St. Francis에서 발표할 예정입니다. 발표 내용은 실시간 웹캐스트를 통해 제공되며, 회사 웹사이트에서 30일 동안 접근할 수 있습니다.
Savara Inc. (Nasdaq: SVRA), une entreprise biopharmaceutique en phase clinique spécialisée dans les maladies respiratoires rares, a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan Healthcare. Le président et CEO de l'entreprise, Matt Pauls, présentera le 15 janvier à 17h15 PT/20h15 ET au Westin St. Francis à San Francisco. La présentation sera disponible en direct via un webcast et restera accessible pendant 30 jours sur le site web de l'entreprise.
Savara Inc. (Nasdaq: SVRA), ein biopharmazeutisches Unternehmen in klinischen Phasen, das auf seltene Atemwegserkrankungen spezialisiert ist, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare-Konferenz bekannt gegeben. Der Vorsitzende und CEO des Unternehmens, Matt Pauls, wird am 15. Januar um 17:15 Uhr PT/20:15 Uhr ET im Westin St. Francis in San Francisco präsentieren. Die Präsentation wird über einen Live-Webcast verfügbar sein und bleibt 30 Tage lang auf der Unternehmenswebsite zugänglich.
- None.
- None.
Date/Time of Presentation: January 15, 5:15pm PT/8:15pm ET
Presenter: Matt Pauls, Chair and Chief Executive Officer, Savara
Location: Westin St. Francis,
The live webcast and subsequent replay will be available on the “Events & Presentations” section of the Company’s corporate website at https://savarapharma.com/investors/events-presentations/ and will be archived for 30 days.
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of a large molecule. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com, X: @SavaraPharma and LinkedIn.
*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241217702030/en/
Media and Investor Relations Contact
Savara Inc.
Temre Johnson, Executive Director, Corporate Affairs
ir@savarapharma.com
Source: Savara Inc.
FAQ
When is Savara (SVRA) presenting at the J.P. Morgan Healthcare Conference 2024?
How long will Savara's (SVRA) J.P. Morgan Healthcare Conference presentation be available online?
Where can I watch Savara's (SVRA) J.P. Morgan Healthcare Conference presentation?
Who is presenting for Savara (SVRA) at the J.P. Morgan Healthcare Conference?
